Latest Market Operators News

QPM Energy Limited and its subsidiaries have entered voluntary administration with McGrathNicol appointed as administrators and FTI Consulting as receivers over key gas-producing entities. The move aims to stabilise operations and explore restructuring options amid ongoing financial distress.

Cann Group has boosted its private credit loan facility by $2 million to facilitate the early redemption of convertible notes, maintaining its debt restructuring momentum.

Advent Energy, in which MEC Resources holds a 37.95% stake, will challenge a Federal Court judgment on the PEP11 offshore gas exploration permit, with its subsidiary Asset Energy leading the appeal.

Lakes Blue Energy is positioning its Wombat Gas Project as a key contributor to Victoria's energy security and emerging AI infrastructure, with a conceptual study projecting a post-tax NPV10 of A$605 million and first gas in early 2029.

Hillgrove Resources' Kanmantoo Copper Mine has reached its targeted 1.8 million tonnes per annum run rate, while the company advances the Emily Star Stage 2 project with a Final Investment Decision expected sooner than planned.

Aureka Limited has completed a Concept Level Study for its Comstock Gold & Silver Project, selecting the Walkers Pit as the preferred site for a low capital, fast-start mining operation. The company has lodged a Prospecting Licence application and is advancing an infill drilling program to upgrade its 56,000-ounce inferred resource.

Sheffield Resources has negotiated further waivers and deferrals on key loan repayments for its Thunderbird Mineral Sands Mine, extending relief on obligations due through mid-2026. However, the outcome of ongoing debt restructuring talks remains uncertain.

Livium is positioning its Envirostream subsidiary to capitalise on the growing battery recycling needs from Australia's booming AI data centre sector, leveraging its EPA-licensed facilities and national network.

AFT Pharmaceuticals surged 22% to NZ$254.7 million revenue in FY26, surpassing profit guidance and securing FDA approval to advance a pivotal injectable iron Phase III trial targeting a $7.4 billion market. The company is poised for further global expansion and product launches in FY27.

AFT Pharmaceuticals delivered a 22% revenue jump in FY26 to NZD 254.7 million, surpassing profit guidance and expanding its footprint to 87 countries. The company is advancing multiple R&D projects, including a pivotal Phase III injectable iron trial, while targeting over NZD 300 million in revenue for FY27.

1414 Degrees has cleared a key technical hurdle at its Aurora Energy Precinct in South Australia, moving its Stage 1 battery storage project into commercial transmission negotiations amid strong interest from major data centre players.

Amaero Ltd’s Federal Court-approved re-domiciliation schemes take effect on 11 June 2026, halting ASX trading of existing shares and paving the way for new US HoldCo CDIs to list.